anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
To facilitate the movement of marine mammals in water, the hind legs were either lost altogether, as in the whales and manatees, or united in a single tail fin as in the pinnipeds (seals). In the whale, the cervical vertebrae are typically fused, an adaptation trading flexibility for stability during swimming.
Maintaining a healthy weight – Proper nutrition – Regular physical exercise – in addition to helping to maintain a healthy weight, sufficient vigorous physical exercise increases cells' sensitivity to insulin, and can thus prevent and possibly revert insulin resistance. Medication – specific medications have been shown to be able to prevent type 2 diabetes. However, the disease can often be delayed through proper nutrition and regular exercise.
Army Reserve The Reserve Land Forces regulations 2016 (amendment number 3) Army Reservist Support Service The All-Party Parliamentary Reserve Forces Group – see their most recent report on the TA The Territorial Army 1967–2000 by Wienand Drenth
=== Toxicity === Just as selenomethionine can be randomly incorporated into proteins, selenocystine can also be mistakenly attached to tRNACys by cysteinyl-tRNA synthetase and incorporated into proteins in lieu of cystine. This causes considerable toxicity. A variant synthase that can distinguish between Cys and Sec helps reduce toxicity.
== Activation == Some, but not all, carboxypeptidases are initially produced in an inactive form; this precursor form is referred to as a procarboxypeptidase. In the case of pancreatic carboxypeptidase A, the inactive zymogen form - pro-carboxypeptidase A - is converted to its active form - carboxypeptidase A - by the enzyme trypsin. This mechanism ensures that the acinar cells wherein pro-carboxypeptidase A is produced are not themselves digested.
Sources: en.wikipedia.org
Some species of starfish can reproduce asexually as adults either by fission of their central discs or by autotomy (self-amputation) of one or more of their arms. Single arms that regenerate a whole individual are called comet forms. The larvae of several species of starfish can reproduce asexually before they reach maturity. They do this by autotomising some parts of their bodies or by budding. Larvae increase asexual reproduction when they sense that food is plentiful. Though this costs time and energy and delays maturity, it allows a single larva to give rise to multiple adults when the conditions are appropriate.
== History == Reduction of biomolecules with trialkyphosphines received little attention for decades because historically available phosphines were extremely malodorous and/or insoluble in water. In 1969, TCEP was reported as an odorless and water-soluble trialkyphosphine suitable for biochemical use, however the potential use of TCEP for biochemical applications was almost totally ignored for decades. In 1991, Burns reported a new convenient synthetic procedure for TCEP, which set off TCEP becoming more widely available and marketed as a "new" reducing agent for biochemical use, & thus TCEP came into more widespread use throughout the 1990s.
=== Ligand removal === In many cases, as in various high-temperature catalytic applications of Au, the removal of the capping ligands produces more desirable physicochemical properties. The removal of ligands from colloidal gold while maintaining a relatively constant number of Au atoms per Au NP can be difficult due to the tendency for these bare clusters to aggregate. The removal of ligands is partially achievable by simply washing away all excess capping ligands, though this method is ineffective in removing all capping ligand. More often ligand removal achieved under high temperature or light ablation followed by washing. Alternatively, the ligands can be electrochemically etched off.
== Criticism == In a 2002 lawsuit against McDonald's, a judge commented that Chicken McNuggets are a "McFrankenstein" creation. The judge identified that rather than being merely chicken fried in a pan, McNuggets included elements not utilized by the home cook, including unusual sounding ingredients such as extracts of rosemary, vitamins (niacin, thiamine mononitrate, riboflavin, and folic acid) all of which are common in enriched flour, and leavening (baking soda, calcium lactate, etc.). The 2004 documentary Super Size Me states that "[o]riginally created from old chickens that can no longer lay eggs, McNuggets are now made from chickens with unusually large breasts. They're stripped from the bone, and ground-up into a sort of 'chicken mash', which is then combined with all sorts of stabilizers and preservatives, pressed into familiar shapes, breaded, deep-fried, freeze-dried, and then shipped to a McDonald's near you." Super Size Me also alleged inclusion of ingredients such as TBHQ, polydimethylsiloxane, and others not used by a typical home cook. This was subsequently restated by CNN. Marion Nestle, a New York University professor and author of What to Eat, says that the ingredients in McNuggets probably pose no health risks. Before August 2016, dimethylpolysiloxane and TBHQ were listed as ingredients in the McNuggets cooking process. According to Lisa McComb, a media relations representative for McDonald's, dimethylpolysiloxane is used as a matter of safety to keep the frying oil from foaming.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.